Cargando…

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). The patients were health care workers who were 32 to 54 years of age...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Nina H., Sørvoll, Ingvild H., Michelsen, Annika E., Munthe, Ludvig A., Lund-Johansen, Fridtjof, Ahlen, Maria T., Wiedmann, Markus, Aamodt, Anne-Hege, Skattør, Thor H., Tjønnfjord, Geir E., Holme, Pål A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112568/
https://www.ncbi.nlm.nih.gov/pubmed/33835768
http://dx.doi.org/10.1056/NEJMoa2104882
Descripción
Sumario:We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). The patients were health care workers who were 32 to 54 years of age. All the patients had high levels of antibodies to platelet factor 4–polyanion complexes; however, they had had no previous exposure to heparin. Because the five cases occurred in a population of more than 130,000 vaccinated persons, we propose that they represent a rare vaccine-related variant of spontaneous heparin-induced thrombocytopenia that we refer to as vaccine-induced immune thrombotic thrombocytopenia.